Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Press Releases
Sort By
Newest First
1 / 150
1 / 150
NKTR-255
Nektar Presents Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia
Nektar Therapeutics
PR-10-24-NI-85
Nov 08, 2024
Clinical Trials
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
Carisma Therapeutics Inc.
PR-10-24-NI-89
Nov 08, 2024
Large Molecule
Johnson & Johnson submits applications seeking approval as subcutaneous monotherapy for high-risk smoldering multiple myeloma
Johnson & Johnson
PR-10-24-NI-88
Nov 08, 2024
Announcement
Bio-Techne To Present At Investor Conferences
Bio-Techne Corporation
PR-10-24-NI-87
Nov 08, 2024
Clinical Trials
Samsung Biologics earns ISO certifications in recognition of business excellence
Samsung Biologics
PR-10-24-NI-86
Nov 08, 2024
Announcement
Celebrating More than a Decade of Excellence at the World ADC Awards – Winners Announcement
World ADC
PR-10-24-NI-77
Nov 08, 2024
Periodontal Disease
Periodontal Disease Treatment Market to Hit USD 3.63 Billion by 2030 with 5.9% CAGR | MarketsandMarkets™
MarketsandMarkets™
PR-10-24-NI-84
Nov 07, 2024
HLA
Global HLA Typing for Transplant Market to Reach USD 2.1 Billion by 2031, Driven by Advancements in Diagnostic Technologies
Market Research Intellect
PR-10-24-NI-83
Nov 07, 2024
Clinical Trials
GenomOncology and Genomenon Partner to Enhance Germline Variant Classification and Genomic Reporting
GenomOncology
PR-10-24-NI-82
Nov 07, 2024
FDA
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
HuidaGene Therapeutics
PR-10-24-NI-81
Nov 07, 2024
Announcement
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
I-Mab
PR-10-24-NI-80
Nov 07, 2024
Clinical Trials
Transposon to Present Results from Phase 2 Study for the Treatment of ALS/FTD at the 7th Annual ALS ONE Research Symposium
Transposon Therapeutics
PR-10-24-NI-79
Nov 07, 2024
Clinical Trials
Precision Biologics to Announce Development of New Monoclonal Antibody (mAb) PB-223 at SITC, Houston, TX, November 7-8, 2024
Precision Biologics
PR-10-24-NI-78
Nov 07, 2024
Financing
Microbiologics Acquires SensID, Expanding Expertise in Diagnostic Quality Controls
Microbiologics
PR-10-24-NI-76
Nov 06, 2024
Clinical Trials
Broad Clinical Labs
Broad Clinical Labs
PR-10-24-NI-75
Nov 06, 2024
Clinical Trials
New SELECT trial analysis with semaglutide 2.4 mg showed a reduction in hospital admissions with heart disease and overweight
Novo Nordisk
PR-10-24-NI-74
Nov 05, 2024
Clinical Trials
OncoResponse to Present Phase 1 Results of Clinical Study of OR502, anti-LILRB2 Antibody, as a Late-Breaker Poster
OncoResponse
PR-10-24-NI-73
Nov 05, 2024
Biomanufacturing
Olon is Ready to Host Productions in the New Facility Dedicated to Ultra-Potent Compounds
Olon
PR-10-24-NI-72
Nov 04, 2024
Bioscience
Neurocrine Biosciences Presents Breadth of Data Over Time Following Treatment With INGREZZA Capsules
Neurocrine Biosciences
PR-10-24-NI-71
Nov 04, 2024
Clinical Treatment
Eisai Completes Submission to US FDA for LEQEMBI Application for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Eisai
PR-10-24-NI-70
Nov 01, 2024